Heterozygous PRKN mutations are common but do not increase the risk of Parkinson’s disease

Assessing the Relationship Between Monoallelic PRKN Mutations and Parkinson’s Risk

(2021) Steven J Lubbe et al.   HUMAN MOLECULAR GENETICS

Mt-Keima detects PINK1-PRKN mitophagy in vivo with greater sensitivity than mito-QC

(2021) Yi-Ting Liu et al.   Autophagy

GP2 : The Global Parkinson's Genetics Program

(2021)   MOVEMENT DISORDERS

Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource

(2021) Hirotaka Iwaki et al.   MOVEMENT DISORDERS

A structural variation reference for medical and population genetics

(2020) Ryan L. Collins et al.   NATURE

Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease

(2020) Eric Yu et al.   MOVEMENT DISORDERS

The genetic architecture of Parkinson's disease

(2019) Cornelis Blauwendraat et al.   LANCET NEUROLOGY

The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population‐Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight

(2019) Sara Bandres‐Ciga et al.   MOVEMENT DISORDERS

Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

(2019) Mike A Nalls et al.   LANCET NEUROLOGY

Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin , PINK1 , DJ1: MDSGene Systematic Review

(2018) Meike Kasten et al.   MOVEMENT DISORDERS

Are PARKIN patients ideal candidates for dopaminergic cell replacement therapies?

(2018) Tilo Kunath et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

The UK Biobank resource with deep phenotyping and genomic data

(2018) Clare Bycroft et al.   NATURE

NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases

(2017) Cornelis Blauwendraat et al.   NEUROBIOLOGY OF AGING

Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications

(2015) Xiaoyu Chen et al.   BIOINFORMATICS

Heterozygote carriers for CNVs inPARK2are at increased risk of Parkinson's disease

(2015) Johanna Huttenlocher et al.   HUMAN MOLECULAR GENETICS

NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases

(2015) Mike A. Nalls et al.   NEUROBIOLOGY OF AGING

UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age

(2015) Cathie Sudlow et al.   PLOS MEDICINE

Compensatory premotor activity during affective face processing in subclinical carriers of a single mutant Parkin allele

(2012) S. Anders et al.   BRAIN

Phenotypic variability ofparkinmutations in single kindred

(2012) Brianada Koentjoro et al.   MOVEMENT DISORDERS

Mutations in PINK1 and Parkin Impair Ubiquitination of Mitofusins in Human Fibroblasts

(2011) Aleksandar Rakovic et al.   PLoS One

Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy

(2010) Matthew E. Gegg et al.   HUMAN MOLECULAR GENETICS

Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin

(2010) Atsushi Tanaka et al.   JOURNAL OF CELL BIOLOGY

Clinical features and [11C]-CFT PET analysis of PARK2, PARK6, PARK7-linked autosomal recessive early onset Parkinsonism

(2010) Ji-feng Guo et al.   NEUROLOGICAL SCIENCES

Olfaction in Parkin heterozygotes and compound heterozygotes: The CORE-PD study

(2010) R. N. Alcalay et al.   NEUROLOGY

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data

(2010) K. Wang et al.   NUCLEIC ACIDS RESEARCH

The Mitochondrial Fusion-Promoting Factor Mitofusin Is a Substrate of the PINK1/Parkin Pathway

(2010) Angela C. Poole et al.   PLoS One

Drosophila Parkin requires PINK1 for mitochondrial translocation and ubiquitinates Mitofusin

(2010) E. Ziviani et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nigrostriatal dysfunction in homozygous and heterozygousparkingene carriers: An18F-dopa PET progression study

(2009) Nicola Pavese et al.   MOVEMENT DISORDERS

Parkin gene therapy

(2009) Hideki Mochizuki   PARKINSONISM & RELATED DISORDERS